[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coagulation-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coagulation-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,75,125,154,180,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100451321","phase-3-a-study-of-tak-330-to-reverse-the-effects-of-factor-xa-inhibitors-for-adults-needing-urgent-surgery-100451321",false,"NCT05156983","A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial With Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation in Patients Requiring Urgent Surgery\u002FInvasive Procedure","Inclusion Criteria:\n\n* Participant or legally authorized representative willing to sign e-consent\u002Fwritten informed consent form.\n* Participants at least 18 years of age at enrollment.\n* Participant currently on treatment with oral Factor Xa inhibitor (rivaroxaban, apixaban, edoxaban).\n* In the opinion of the surgeon, the participant requires an urgent surgery\u002Fprocedure that is associated with high-risk of intraoperative bleeding within 15 hours from the last dose of Factor Xa inhibitor and requires a reversal agent for suspected direct oral Factor Xa inhibitor-related coagulopathy. For participants who are beyond the 15-hour window, eligibility requires proof of elevated plasma anti-Factor Xa (FXa) levels using either specific direct oral anti-coagulant (DOAC)-calibrated (apixaban, rivaroxaban or edoxaban) anti-FXa levels of greater than (\\>) 75 nanograms per milliliter (ng\u002FmL), or heparin calibrated anti-FXa assay levels of \\>0.5 international unit per milliliter (IU\u002FmL) at screening.\n* Women of childbearing potential should have a negative pregnancy test documented prior to enrollment.\n\nExclusion Criteria:\n\n* The participant has an expected survival of less than 30 days, even with best available medical and surgical care.\n* Recent history (within 90 days prior to screening) of venous thromboembolism, myocardial infarction (MI), disseminated intravascular coagulation (DIC), ischemic stroke, transient ischemic attack, hospitalization for unstable angina pectoris or severe or critical coronavirus 2 (SARS-CoV-2) infection.\n* Active major bleeding defined as bleeding that requires surgery or transfusion of \\>2 units of packed red blood cell (PRBC) or intracranial hemorrhage with the exception of subacute and chronic subdural hemorrhages with a Glasgow Coma Score (GCS) greater than or equal to (\\>=) 9.\n* Polytrauma for which reversal of Factor Xa-inhibition alone would not be sufficient to achieve hemostasis.\n* Known prothrombotic disorder including primary antiphospholipid syndrome, antithrombin-3 deficiency, homozygous protein C deficiency, homozygous protein S deficiency, and homozygous factor V Leiden.\n* Known bleeding disorder (example, platelet function disorders, hemophilia, Von Willebrand disease, or coagulation factor deficiency).\n* Platelet count less than (\\\u003C) 50,000 per microliter (\u002FmcL).\n* History of heparin-induced thrombocytopenia.\n* Administration of procoagulant drugs (example, non-study prothrombin complex concentrates (PCCs), recombinant Factor VIIa) or blood products (transfusion of whole blood, fresh frozen plasma, cryoglobulins, plasma fractions, or platelets) within 7 days before enrollment. (Note: administration of PRBCs for hemoglobin correction, tranexamic acid or aminocaproic acid are not exclusion criteria).\n* Planned use of procoagulant drugs (example, Vitamin K, non-study PCCs, recombinant Factor VIIa) or blood products (transfusion of whole blood, fresh frozen plasma, cryoglobulins, plasma fractions, or platelets) after enrollment but before the 24±4 hours hemostatic assessment (Key secondary endpoint). Planned administration of tranexamic acid (TXA) or aminocaproic acid after randomization but before the start of IP infusion, should be noted during randomization to properly stratify these participants in the interactive response technology (IRT). Planned administration of TXA or aminocaproic acid after start of IP infusion but before the 24±4 hours hemostatic assessment is prohibited. Administration of any of the above products before the 24±4 hours hemostatic assessment will impact the assessment of hemostasis. Administration of PRBCs for hemoglobin correction, is not an exclusion criterion.\n* Administration of unfractionated heparin within 2 hours before randomization or low molecular weight heparin within 6 hours before randomization.\n* Hypersensitivity to PCC constituents or any excipient of TAK-330.\n* Participants with history of confirmed immunoglobulin A (IgA) deficiency with hypersensitivity reaction and antibodies to IgA.\n* Septic shock as defined by persistent hypotension requiring vasopressors to maintain mean arterial pressure (MAP) \\>=65 millimeters of mercury (mmHg) and having blood lactate \\>2 millimole (mmol) despite adequate volume resuscitation.\n* Acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C)\n* Renal failure requiring dialysis\n* Any other condition that could, in the opinion of the investigator, put the participant at undue risk of harm if the participant were to participate in the study.\n* Participation in another clinical study involving an investigational product or device within 30 days prior to study enrollment, or planned participation in another clinical study involving an investigational product or device during the course of this study. Participation in an observational study is not an exclusion criterion.\n* The use of PROTHROMPLEX TOTAL as SOC 4F-PCC.\n* Women who are breastfeeding at the time of enrollment.","ALL","18 Years",{"count":19,"type":20},440,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery\u002Finvasive procedure.\n\nThe participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery.\n\nPatients participating in this study will need to be hospitalized. They will also be contacted (via telehealth\u002Fphone call) 30 days after the surgery.",[26],"Coagulation Disorder",[28],"Reversal of Factor Xa inhibitors","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2022-08-24",{"date":37,"type":20},"2028-08-30",{"name":39,"class":40},"Takeda","INDUSTRY",64,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100553123","phase-4-swift---swiss-factor-xiii-trial-in-pph-100553123","NCT06481995","SWIFT - SWIss Factor XIII Trial in PPH","Early Factor XIII Replacement in Postpartum Hemorrhage: Multi-center, Randomized, Controlled, Investigator-initiated Trial","SWIFT","Inclusion Criteria:\n\n* planned vaginal delivery\n* singleton vital pregnancy\n* gestational age at delivery \\>= 30+0 weeks\n* maternal weight at admission for delivery \\\u003C100 kg\n\nExclusion Criteria:\n\n* Antithrombotic therapy in pregnancy (therapeutic dosage) until admission for delivery (LMWH, UFH)\n* diagnosis of preeclampsia (ISSHP classification , eclampsia or HELLP syndrome),\n* known history of deep vein thrombosis or pulmonary embolism,\n* known diagnosis of bleeding disorder or thrombophilia,\n* known thrombocytopenia during second half of pregnancy with thrombocytes \\\u003C 100 G\u002FL,\n* known anemia during second half of pregnancy with Hb\\\u003C80 g\u002FL,\n* known sickle cell disease,\n* known malignant tumor(s),\n* participation in another study with investigational drug within the 30 days preceding and during the present study,\n* inability to follow the procedures of the study, e.g. due to language problems,\n* known or suspected non-compliance, drug or alcohol abuse.\n\nExclusion criteria prior randomization\n\n* Maternal fever ≥39.0°C\n* unplanned cesarean delivery is performed,\n* Measured Blood Loss remains \\\u003C 700 mL after administration of 1g tranexamic acid .\n* Postpartum hemorrhage due to occult bleeding (intra-abdominal, retroperitoneal, parametric),","FEMALE",{"count":52,"type":20},988,[54],"PHASE4","The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).\n\nSummary of current body of evidence:\n\n* Morbidity and mortality due to PPH is rising.\n* Current guidelines focus on replenishment of fibrinogen as an initial step in the treatment of PPH-related coagulopathy, despite non-conclusive evidence in all prospective trials.\n* Trials from other specialties demonstrate a significant impact of FXIII on perioperative bleeding complications; a previous study at the University Hospital Zurich showed that pre-partum factor XIII activity had a strong association to postpartum blood loss.\n\nTherefore, this nationwide, multi-center, randomized, controlled trial in multiple perinatal centers across Switzerland will be conducted. The goal is to determine if postpartum blood loss and PPH-related complications can be reduced by replenishing FXIII.\n\nAll participating women receive, according to the national guideline, 1g tranexamic acid (TXA) i.v. in case of PPH (measured blood loss \\[MBL\\] ≥ 500 mL) during the pre-study phase. Randomization takes place if bleeding continues and exceeds 700mL. The intervention group then receives FXIII (Fibrogammin®) according to approved dosage in addition to obstetric standard of care treatment for causes of PPH; the control group receives only standard of care treatment.",[57,26,58,59,60],"Postpartum Hemorrhage","Coagulation Factor Deficiency","Hemorrhage","Postpartum Complication",[62,63],"Postpartum hemorrhage","coagulation factor XIII","2026-04-21",{"date":66,"type":33},"2026-04-27",{"date":68,"type":33},"2024-07-09",{"date":70,"type":20},"2028-12-31",{"name":72,"class":73},"Christian Haslinger","OTHER",9,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"0 Years","20 Years",{"count":87,"type":20},5000,"OBSERVATIONAL","The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,26,114],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Down Syndrome","2026-03-31",{"date":117,"type":33},"2026-04-06",{"date":119,"type":33},"2020-03-05",{"date":121,"type":20},"2027-07",{"name":123,"class":73},"Duke University",51,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100615121","phase-3-phase-3-trial-of-vmx-c001-vs-usual-pharmacological-care-in-patients-taking-a-fxa-direct-oral-anticoagulant-who-require-urgent-surgery-with-or-without-heparin-100615121","NCT07288489","Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","A Phase 3 Prospective Randomised Clinical Trial of VMX-C001 vs Usual Pharmacological Care in Patients Receiving a FXa Direct Oral Anticoagulant (FXa DOAC) Who Require Urgent Surgery or Other Invasive Procedure That is Associated With a High Risk of Bleeding, With or Without Planned Administration of Heparin (EQUILIBRIX-S)","EQUILIBRIX-S","Inclusion Criteria:\n\n1. Male or female patient aged ≥18 years.\n2. The patient or legally authorised representative (LAR) has given written informed consent.\n3. The patient requires urgent surgery\u002Fprocedure for which the risk of bleeding is considered high and for which haemostasis is considered necessary.\n4. The patient has a significant FXa DOAC level at the time of procedure.\n5. The patient would require treatment (usual pharmacological care) to restore coagulation for the required procedure.\n6. The patient must be willing to use appropriate contraception.\n\nExclusion Criteria:\n\n1. The patient is known for any reason, other than administration of a FXa DOAC, to have an increased risk of bleeding compared to a patient in a similar clinical situation.\n2. The patient has received any non FXa DOAC anticoagulants within 7 days of Screening or has received heparin (UFH or LMWH) within 3 days of Screening.\n3. The patient has received any of the prespecified medications not allowed in the 7 days prior to Randomisation.\n4. The patient was treated with an investigational drug \\\u003C30 days or 5 half-lives, whichever is longer, prior to Screening.\n5. Expected survival, in the Investigator's judgement, is \\\u003C3 months due to comorbidity.\n6. Patients in whom the Investigator considers it is not possible to estimate the expected blood loss.\n7. Known \"Do Not Resuscitate\" order or similar advanced directive.\n8. Cardiogenic shock at the time of screening unless related to the need for the required procedure.\n9. The patient has sepsis (including severe sepsis or septic shock) at the time of screening.\n10. The patient is pregnant or a lactating female.\n11. Known hypersensitivity to any component of VMX-C001 or hamster proteins.\n12. Patients who, in the opinion of the Investigator, should not participate in the study for any other reason, or inability to comply with the protocol.\n13. Prior exposure to VMX-C001.",{"count":134,"type":20},800,[23],"The goal of this clinical trial is to learn if VMX-C001 works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that carry a high risk of bleeding. The main question it aims to answer is:\n\n● What is the proportion of participants in whom the stopping of bleeding was classed as good or excellent during the procedure, as judged by a group of experts who did not know which treatment was given?\n\nResearchers will compare a fixed dose of VMX-C001 to the usual treatment that would be given for the required procedure.\n\nParticipants will:\n\n* Be given either a fixed dose of VMX-C001 or usual treatment before they undergo the required procedure in theatre\n* Have regular clinical assessments, including laboratory tests, during their hospital stay following the procedure\n* Return to the clinic for a check-up and tests approximately 28 days after the procedure was conducted.",[138,26],"Blood Loss, Surgical",[140,141,142],"Direct oral anticoagulant (DOAC)","Human coagulation factor","Surgery","NOT_YET_RECRUITING","2026-02-25",{"date":146,"type":33},"2026-02-27",{"date":148,"type":20},"2026-03",{"date":150,"type":20},"2031-01",{"name":152,"class":40},"VarmX B.V.",26,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100402774","the-utility-of-thromboelastography-in-traumatic-brain-injury-100402774","NCT04524637","The Utility of Thromboelastography in Traumatic Brain Injury","The Utility of Thromboelastography for Predicting the Risk of Coagulation-Related Damages Secondary to Traumatic Brain Injury","Inclusion Criteria:\n\n* Patients who are delivered to hospital within 24 hours after head trauma\n* Patients whose abbreviated injury score (AIS) for other body regions is 3 or less are considered to be isolated traumatic brain injury\n\nExclusion Criteria:\n\n* Patients with existing prior neurological disease\n* Patients with known coagulation disorders\n* Patients on anticoagulants and medications known to affect coagulation function within 30 days before trauma\n* Patients receiving blood components prior to blood draw\n* Patients who deteriorate and die before determining whether coagulation- related damage exists","80 Years",{"count":163,"type":20},500,"Hemocoagulation disorder is recognized to have crucial effects on hemorrhagic or ischemic diseases. Coagulation-related damages secondary to traumatic brain injury are common and severe secondary insults of head trauma and often leads to a poor prognosis. In this study, we sought to assess if posttraumatic hemocoagulation disorders determined using thromboelastography are associated with coagulation-related damages secondary to traumatic brain injury, and evaluate their influence on outcome among patients with head trauma. Based on above results, prediction models or risk scoring systems will be further developed and validated to predict coagulation-related damages secondary to traumatic brain injury.",[166,26],"Traumatic Brain Injury",[168,26,166,169],"Thrombelastography","Coagulation-related damages","2025-03-13",{"date":172,"type":33},"2025-03-17",{"date":174,"type":33},"2018-09-01",{"date":176,"type":20},"2027-12-31",{"name":178,"class":73},"Shanghai 6th People's Hospital",1,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":179},"100488820","extracellular-vesicles-and-dysregulated-coagulation-in-the-prediction-of-stroke-100488820","NCT05645081","Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke","PREDICT-EV; the Association of Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke","PREDICT-EV","The inclusion criteria for phase 1 (initial patient recruitment) will be:\n\n1. Patients with or without diagnosis of TIA made by a physician working in stroke medicine, sufficiently so to start post-TIA care or so that no further investigation is thought necessary to confirm or refute the diagnosis.\n2. TIA confirmed patient has been prescribed antiplatelet drugs or anticoagulants.\n3. Patients must be aged \\> 18 years.\n4. Patients are taking an ordinary diet by mouth.\n\nThe inclusion criteria for phase 2 (patient representing with stroke) will be:\n\n1. Radiological evidence, on CT and\u002For MR imaging of the brain of cerebral infarction, with or without secondary haemorrhage.\n2. The underlying mechanism of cerebral infarction is embolic from a cardiac source (e.g. atrial fibrillation), atherothromboembolic (from aorta or other large vessels in the neck) or in-situ thrombosis. No further investigations are thought necessary to confirm or refute the diagnosis.\n3. No further investigations are thought necessary to confirm or refute the diagnosis.\n4. Patients must be aged \\>18 years.\n5. Patients must not be pregnant or breast feeding.\n6. Patients are taking an ordinary diet by mouth. Exclusion Criteria\n\nThe Exclusion criteria for phase 1 (initial patient recruitment) will be:\n\n1. Inability to give consent.\n2. Inability to feed by mouth.\n3. Short life expectancy.\n4. Pregnancy or breastfeeding.\n5. Symptoms are readily explained by medical problems not involving focal cerebral ischaemia.\n\nThe Exclusion criteria for phase 2 (patient representing with stroke) will be:\n\n1. Patients who have not previously given consent for follow up blood sampling.\n2. Patients who are unable to feed by mouth.\n3. Patients in whom life expectancy is short.\n4. Patient is pregnant or breast feeding.",{"count":189,"type":20},360,"Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK. 90% of strokes are preventable, leading to national focus on programmes including \"The National Stroke Programme\" to act on preventing, treating, and improving post-stroke care. Importantly, over 25% of ischaemic stroke sufferers have previously had a Transient Ischaemic Attack (TIA), which presents the biggest concern for TIA patients. There are no measures which reliably identify TIA patients most likely to suffer a stroke. Novel biomarkers for predicting stroke are key to addressing this problem. The PREDICT-EV study aims to screen 300 TIA patients and follow them over 12-months. The investigators will determine if a novel biomarker we've identified to increase thrombotic risk (endothelial derived extracellular vesicles) and the resulting increased prothrombin time is associated with patients at highest risk of stroke.",[192,193,26],"Stroke, Ischemic","Transient Ischemic Attack",[195,193,196,197],"Stroke Risk","Extracellular Vesicles","Pro-Thrombotic Risk","2024-08-19",{"date":200,"type":33},"2024-08-20",{"date":202,"type":33},"2021-10-01",{"date":204,"type":20},"2027-09-01",{"name":206,"class":207},"Cwm Taf University Health Board (NHS)","OTHER_GOV",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":88,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":179},"100449984","the-endocarditis-aumc-data-collection-100449984","NCT05139589","The ENDOCARDITIS AUMC Data Collection","The ENDOCARDITIS AUMC Data Collection : a Matched Cohort Study on Perioperative Coagulation in Conservatively and Surgically Treated Patients With Valvular Dysfunction, With and Without Infective Endocarditis","ENDO_AUMC","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Dutch or English speaking\n* All patients with infective endocarditis admitted to Amsterdam UMC in the study period\n* All patients with infective endocarditis scheduled for cardiac valve surgery compared to a matched cohort of patients scheduled for similar surgery due to non-infectious indication in Amsterdam UMC in the same period\n\nExclusion Criteria:\n\n* Previous history of coagulation disorders",{"count":217,"type":20},3000,"10 Years","The investigators will compare patients with and without infective ndocarditis undergoing valve surgery and evaluate factors that may help optimise perioperative care of these high-risk patients.",[221,26,222],"Endocarditis","Valve Disease, Heart","2023-07-24",{"date":225,"type":33},"2023-07-25",{"date":227,"type":20},"2023-08-06",{"date":229,"type":20},"2030-12-31",{"name":231,"class":73},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]